Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 3, 2020

Relief Therapeutics and NeuroRx start enrolment for Covid-19 trial

Relief Therapeutics and its partner NeuroRx have started patient enrolment and treatment in a Phase IIb/III clinical trial of RLF-100 to treat acute respiratory distress syndrome (ARDS) caused by Covid-19.

Relief Therapeutics and its partner NeuroRx have started patient enrolment and treatment in a Phase IIb/III clinical trial of RLF-100 to treat acute respiratory distress syndrome (ARDS) caused by Covid-19.

The first patients are being treated at the University of Miami Miller School of Medicine in Florida, US. The partners are recruiting patients on mechanical ventilation for the  trial.

RLF-100 is a formulation of a synthetic human vasoactive intestinal polypeptide (VIP) called Aviptadil, which acts on alveolar type 2 cells in the lungs.

Various animal models of lung injury and lung disease showed that VIP blocks inflammatory cytokines and protects pulmonary epithelial cells in the air sacs of the lungs.

NeuroRx CEO Jonathan Javitt said: “RLF-100 previously showed promising Phase I results in ARDS related to sepsis and promising Phase II results in the treatment of other inflammatory lung conditions.

“Aviptadil specifically binds to the cells in the lung that are essential to transmitting oxygen to the body and to making surfactant that is essential to oxygen exchange (the Alveolar Type II cells). These are the same cells that are targeted and killed by the SARS-CoV-2 virus.”

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The multi-centre, randomised, placebo-controlled Phase IIb/III trial is set to enrol 120 participants, who will receive intravenous (IV) RLF-100 plus maximal intensive care or placebo with maximal intensive care.

The primary endpoints of the study will be mortality and index of respiratory distress, while secondary endpoint will include TNFa levels and multi-system organ failure free days.

Relief Therapeutics and NeuroRx are working to trial and boost access to RLF-100 in the EU, UK, Russia and Australia.

Last month, Relief Therapeutics announced that a Phase II trial of Aviptadil is being performed at New York University Langone (NYU Langone Health) for the treatment of Covid-19-related ARDS.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU